ean virtual 2020

6th Congress of the European Academy of Neurology

May 23 - 26

Time for Action

Predict. Prevent. Repair.



Pocket Programme

REASONS TO BECOME AN INDIVIDUAL MEMBER OF EAN

- Get connected
- Boost your career
- Save money
- Keep learning
- Shape the future
- Make a difference
- Go global



ean congress



General Information

ABSTRACT VOLUME

All accepted abstracts are published as a supplement to the *European Journal of Neurology*.

CME CERTIFICATE + ATTENDANCE TRACKING REPORT

Please evaluate all sessions that you have attended immediately. You will receive a link to your certificate. CME Certificates will be available only for sessions attended from 23-26 May 2020.

If you have any questions, please visit the EAN Virtual Booth during the congress or contact us at headoffice@ean.org.



CME Certificates, including a record of attendance, will be available only to the participants of the live streamed sessions (23–26 May 2020) who have evaluated them immediately. Evaluation is possible until Tuesday, 26 May 2020, 23:59 CET.

CONGRESS SESSIONS and ePRESENTATIONS

There will be scheduled slots for all presentations during the virtual congress. There will be a chat function as well as a live Q&A for all sessions during specified times. The presenters are kindly asked to be present during the scheduled time to ensure interaction with the audience.

At the scheduled timeslot of the session, the chairperson will open the session and introduce the speakers. At all times there is a live-chat available, where all participants can contribute to the session or ask questions.

Please note that it is also possible for all participants to send a private message with questions to the lecturers, which will be answered after the congress and published on the platform so all EAN members can benefit from it. If the lecturer is not available to be online at the scheduled timeslot, we will also forward the questions from the chat to them and publish the answers after the congress.

ADDITIONAL INFORMATION FOR ePRESENTATION AND ePOSTER SESSIONS

All ePresentations and ePosters will be available throughout the congress and a direct contact button will be available to ask questions to the presenters. Speakers and chairpersons will be available during the dedicated slots (please see programme).

All ePoster sessions are listed in the online programme.

During the timeslot, the pre-recorded presentations will be played, and the live Q&A function will be available for interaction between chair, speakers and audience.

All information and illustrations in this Pocket Programme represent the latest available at the time of print.





Virtual Congress 2020 – how to be involved

Take part and benefit from our newly created virtual items:

Join us at the virtual EAN booth

Welcome to the EAN Virtual Booth: Visit every part of the Booth to find out more about the EAN and its 4 different parts. Download all flyers and gain a community feeling with special features. Book a 5-minute slot for a personal Q&A, our staff will be there for you.

HOME

Get all information on our different membership programmes, people behind EAN, the EAN Board as well as the EAN Head Office.

MEET

Information on our next congress destinations and how to become a part of future EAN activities. Seize this opportunity to meet other members of the EAN community!

LEARN

Find out more about all educational activities EAN has to offer for you - from study programmes outside the EAN congress, online learning possibilities or fellowships.

RESEARCH

Information on EAN guideline production and EAN Scientific Panels - not only on panel membership but also what these panels do and plan to do in the future.

Use the virtual #printer:

Post your photos with **#EAN2020** and see how it will be printed at the EAN Headoffice and ready for you to be picked up at next years' congress.

Check out the EAN Junior suite:

There will be many items for our future junior neurologist: from daily dances, print patterns, how-to and DIY-videos and sing-alongs. Your kids will love it!

Compete in this years' virtual EAN BrainChallenge:

Take part in this years' one-and-only chance to participate in the game and get as many points as possible.

Activities of Resident and Research Fellow Section (RRFS)

Visit the virtual RRFS booth

During the virtual congress, you can get up-to-date information about membership, travel grants, education and other activities.

National representatives meeting

13:00 - 14:00 - Saturday, 23 May

All RRFS National Representatives are invited to join this meeting as well as all RRFS members, who are interested to become an RRFS National Representative. A link to join this meeting is sent to all participants.

Special Session

16:45 - 18:15, Room CbW - Sunday, 24 May

Round Table Discussion with former EAN Fellowship winners

General Assembly

14:15 - 15:00 - Monday, 25 May

All RRFS members are invited to join the RRFS General Assembly to vote the next treasurer of the RRFS office. A link to join this meeting is sent to all participants.

RRFS at the Scientific theatre

Several talks by RRFS members are given at the Scientific Theatre, please see the complete schedule.

sat 23

- sun 24 May

mon 25 May





Saturday, 23 May



			•
\sim	CCIA	n Ove	r\/IQ\A

Auditorium	Oslo	Vienna	Lisbon	Amsterdam	Copenhagen	Berlin	Budapest	CbW Room	Seville	Paris	HoC room	Helsinki	Istanbul
FW 01	laS 01	FW 02	FW 03	SpS 01	FW 04	FW 05	FW 06	CbW 01		FW 07	HoC 01		
	Differential diagnosis in neurological	08:00 - 09:30 Overarching theme: Can we protect and repair the brain after stroke?	08:00 - 09:30 EAN/MDS- ES: Axial Symptoms and Cognition in Parkinson's Disease	8:00 - 09:30 WHO Strate- gies in brain diseases: non- communicable diseases and universal healthcare coverage	08:00 - 09:30 EAN/EFAS: Autonomic nervous system and digestive tract: New insights	08:00 - 09:30 Understanding apraxia	08:00 - 09:30 EAN/EANM: Neuroimaging in dementia: what are the news and what is the perspec- tive?	08:00 - 09:30 Continuous EEG in critical- ly ill patients		08:00 - 09:30 Neuronal ceroid lipofuscinosis (NCL): focus on innovative treatments	08:00 - 09:30 EAN / IFCN- EMEAC: Nerve and muscle sonography - Level 2		
SYMP 01	SYMP 02	SYMP 03			SYMP 04							3DS	
Innovative treatment approaches of inherited	10:00 - 12:00 EAN/MDS-ES: Movement disorders in the emergency room	10:00 - 12:00 EAN/IFCN- EMEAC: Neurophy- siology and non-invasive brain stimulati- on (NIBS)			10:00 - 12:00 Promoting structural repair and func- tional recovery in multiple sclerosis			-10:00 Coffee brea 6:45 Coffee break			е	10:00 - 10:30 Sanofi Genzyme - Will the real MS please stand up?	
EPR 101	SAT SYMP	SAT SYMP	SAT SYMP		EPR 102	EPR 103	EPR 104				EPR 105	EPR 106	EPR 412
Ageing and dementia 1	12:15 - 13:15 Novartis - Un- covering hidden progression in MS: maxi- mising the pa- tient-physician partnership	12:15 - 13:15 Eli Lilly - Pre- dict, Prevent, CONQUER: Beyond Head Pain	12:15 - 13:15 GW Pharmaceut An evolving land atment of Drave and Lennox-Gas (LGS): the influe patient care	lscape in the tre- t syndrome (DS) taut syndrome	12:30 - 13:20 Autonomic nervous system disorders 1	12:30 - 13:30 Cerebrovascu- lar diseases 1	12:30 - 13:30 Cerebrovascu- lar diseases 2				12:30 - 13:25 Child neurology/ developmental neurology; Clinical neuro- physiology	12:30 - 13:20 Cognitive neurology/neu- ropsychology 1	12:45 - 13:45 Movement Disorders 2
	SAT SYMP	SAT SYMP		SAT SYMP						OS	HoC 02	os	
how treatm	nuscular atrophy: nent expectations	13:45 - 14:45 Novartis - Maint management du global healthcris	ring times of a	13:45 - 14:45 Celgene BMS - A disease activity f prognosis of pati Multiple sclerosi	or an accurate ents with					14:30 - 16:30 Infectious diseases	14:45 - 15:45 EAN / IFCN - EMEAC: Needle EMG - Level 1	14:45 - 16:30 Neuromuscular junction disea- ses; peripheral nerve disorders	
TC 01			SpS 03	TC 02	TC 03	TC 04	SpS 02	CbW 02			HoC 03		
15:00 - 18:15 Antibodies: from autoimmune encephalitis to demyelinating myelopathies - Level 2			15:00 - 16:30 MDS-ES: European Basal Ganglia Club	EAN / EFAS: How to approach disorders of the autonomic	can improve detection, prevention	15:00 -18:15 Diagnostic and prognostic evaluation of early dementia and mild cogni- tive impairment	15:00 - 16:30 Acute Neurology	15:00 - 16:30 Neuro-ophthal- mological mimickers			16:00 - 17:00 EAN / IFCN- EMEAC: Transcranial magnetic stimu- lation - Level 1		
		os	os		and potentially repair neurolo-	- Level 1	SpS 04			CdS	HoC 04	os	
		16:45 - 18:00 Headache and pain	16:45 - 18:15 Movement Disorders 1		gical diagnoses - Level 3		16:45 - 18:15 The care of Rare Neurolo- gical Diseases, 2020			16:45 - 18:15 EAN / EAPC: on - breaking bad discuss the future	EAN / IFCN - EMEAC:	17:00 - 18:15 Cerebro- vascular diseases 1	
EPR 107	EPR 108	EPR 109	EPR 110	EPR 111	EPR 120	EPR 113	EPR 114	EPR 115	EPR 116	EPR 117	EPR 118	EPR 119	EPR 112
	18:30 - 19:30 Epilepsy 1	18:30 - 19:20 Headache and pain 1	18:30 - 19:20 Headache and pain 2	18:30 - 19:35 Motor neurone diseases	18:30 - 19:25 Neuro-ophthal- mology/ neuro- otology	18:30 - 19:25 MS and related disorders 1	18:30 - 19:25 MS and related disorders 2	18:30 - 19:25 MS and related disorders 3	18:30 - 19:10 Muscle and NMJ disease 1	18:30 - 19:25 Neuroimaging 1	18:30 - 19:15 Neuro- immunology 1	18:30 - 19:20 Neurol. manife- stations of sys- temic diseases	18:30- 19:30 Movement Disorders 1






Sunday, 24 May



Session Overview

Auditorium	Oslo	Vienna	Lisbon	Amsterdam	Copenhagen	Berlin	Budapest	CbW Room	Seville	Paris	HoC room	Helsinki	Istanbul
New Neurologi-	stroke patients	FW 08 08:00 - 09:30 Overarching theme: Prediction, prevention and personalised treatment approaches of neuromuscular disorders	Overarching theme: EAN/AAN:	FW 10 08:00 - 09:30 Large scale brain networks as a readout of cognitive changes and treatment manipulations in Parkinson's disease		Overarching theme: EAN / ILAE:	FW 12 08:00 - 09.30 Vector-borne neuro-infec- tions	LEAN/ MDS-ES: Diagnosis and	SpS 12 08:00 - 09:30 European Brain Council: Severe patients in neurology and psychiatry			3DS 09:30 - 10:00 Celgene BMS - Gathering core, clinical data sets: Magnetic Resonance Imaging, cognition, McDonald 2017 criteria and diagnosis	
EPR 201	SAT SYMP	SAT SYMP	SAT SYMP	SAT SYMP	EPR 202	EPR 203	EPR 204	EPR 205			EPR 206	3DS	[
	12.15 - 13.15 Roche - How can we ensure MS patient care continues to advance through these challenging times?	12.15 - 13.15 Biogen - Out-	12.15 - 13.15 Biogen - The early diagnosis of Alzheimer's disease: delineating the cause of memo- ry impairmen	12.15 - 13.15 Bial - Moving from the peri- phery to the core of the mat- ter – where does opicapone fit in Parkinson's disease?	12:30 - 13:20 Autonomic nervous system disorders 2	12:30 - 13:25 Cerebrovascu-	12:30 - 13:20 Cerebrovascu- lar diseases 4	12:30 - 13:20 Cognitive neurology/neu- ropsychology 2		13.00-14.30 Challenges for women in neu- rology (Lunch Session)	12:30 - 13:30 Epilepsy 2	13.15 - 13.45 Sanofi Genzyme - A brain-first perspective in MS	
	SAT SYMP	SAT SYMP	SAT SYMP	SAT SYMP									
be done to pr systems treat Alzheir	13.45-14.45 or Not? What can repare health care for the diagnosis, tment and care of mer's disease in a disease modifying therapies?	Teva - Anti-cal- citonin gene-re- lated peptide monoclonal antibodies and the evolving	13.45-14.45 Alexion - Complement inhibition in neurological disease: can we prevent damage and regain control? Key findings from phase 3 studies	13.45-14.45 Biogen - MS looking forward: Innovations for individualised patient care					offee break – foru ffee break – forum				
SpS 13		TC 05	TC 06	SYMP 09	TC 07		TC 08	CbW 04	os	TC 09	CdS 01	os	os
15:00 - 16:30 COVID-19 infection and possible neurological consequences		EAN / MDS- ES: Differential diagnosis and therapy of movement disoders for	Preventing critical complications of neurological patients in intensive care -	EAN / EHF:	00 - 16:30 N / EHF: met needs in te treatment disorders -		15:00 - 18:15 Neuroinfections under risk behaviours - Level 2	15:00 - 16:30 Myasthenia gravis: diagno- stic mimics	15:00 - 16:30 Sleep disor- ders 1	15:00 - 18:15 The rapid expansion in diagnostic genetics; geno- me sequencing, repeat expan-	15:00 - 16:30 EAN / EFAS: The role of the neurologist in the area of big data	15:00 - 16:00 Epilepsy 1	15:00 - 16:00 MS and related disorders 1
		general neuro- logists - Level 2	Level 2/3 OS 16:45 - 18.: Cognitive ne		ogy/neuropsy- and dementia 1	CONT 01 16:45 - 17:30 EAN / EFIC: Pain reserach				sions, rapid initiation, and interpretation - Level 3	evaluation of pr	3DS 16.15 - 16.45 IS - Risk stratifica rognostic markers patients with Mu	to assess risk of
OS	laS 05		SAT SYMP	SAT SYMP		CONT 01b		SpS 07	os		HoC 06	os	os
				2:00 18:30 - 20:00 Arvelle Therapeutics - Drug resistant		17:40 - 18:25 Decisions in MS		16:45-18:15 l Research Fellow ish your potential with EAN!	nervous system	logical disord	16:45-18:45 essment of neuro- ers with machine nologies - Level 2	Cerebrovascu- lar diseases 2	17:00-18:15 Clinical neuro- physiology
EPR 207	EPR 208	EPR 209	Amyloidosis. An update from	are we today?	EPR 210	EPR 211	EPR 212	EPR 213	EPR 214	EPR 215	EPR 216	EPR 217	EPR 218
18:30 - 19:25 Headache and pain 3	18:30 - 19:20 Headache and pain 4	18:30 - 19:05 Infectious Diseases 1	a neurologist's perspective	eurologist's	18:30 - 19:30 Movement disorders 3	18:30 - 19:30 Movement disorders 4	18:30 - 19:25 MS and related disorders 4		18:30 - 19:25 MS and related disorders 6	18:30 - 19:15 Muscle and NMJ disease 2	19:00 - 20:00 Epidem.; Toxi- col.; Trauma	18:30 - 19:15 Neurogenetics 1	18:30 - 19:25 Neuroimaging 2





Session Overview

Auditorium	Oslo	Vienna	Lisbon	Amsterdam	Copenhagen	Berlin	Budapest	CbW Room	Seville	Paris	HoC room	Helsinki	Istanbul
FW 14	laS 06	FW 15	FW 16	FW 17	FW 18	FW 19	SpS 08	CbW 05	SpS 09	FW 20	HoC 07	3DS	
08:00 - 09:30 New insights into vascular cognitive impairment (VCI): from basic science to prevention and treatment	08:00 - 09:30 EAN / EFAS: How to manage symptoms of autonomic failure	How is	08:00 - 09:30 Genetic testing in epilepsy in 2020: When to ask for it and how it can contribute to epilepsy management	08:00 - 09:30 EAN / ECRIMS: The emerging importance of "other cells" in multiple sclerosis	Brain-Compu- ter Interfaces	08:00 - 09:30 EAN / EANO: Emerging neurological complications in treatments of oncology	08:00 - 09:30 History of neuroscience	08:00 - 09:30 Neurological consultant in the ICU	08:00 - 09:30 Relevance of sex differences in neurological disorders	08:00 - 09:30 Fitness to drive in neurological disorders		09:30 - 10:00 Celgene BMS - Risk stratification: what can bio- markers tell us with regard to progression and long-term outcome risks	
PLEN 03 10:00 - 12.00 Overarching the	eme: Time for Actio	on: Predict. Preve	nt. Repair.										
EPR 220			SAT SYMP		EPR 221	EPR 222	EPR 223		EPR 301		EPR 302		EPR 303
12:30 - 13:15 Neuro-onco- logy 1		Perspectives o gnition of Adva Disease and Con	12:15-13:15 ates and Debates: n the Early Reco- nced Parkinson; stituous Dopami- ulation Therapies		12:30 - 13:25 Neurorehabili- tation	12:30 - 13:25 Peripheral nerve disorders 1	12:30 - 13:35 Sleep disor- ders 2		12:30 - 13:25 Cerebrovascu- lar diseases 5		12:30 - 13:25 Cerebrovascu- lar diseases 6	3DS 13.15-13.45 Sanofi Genzyme - Brain pene- trance, the new road to take?	12:30 - 13:20 Cognitive neurology/neu ropsychology 3
	SAT SYMP 13.45-14.45 Merck - Is it time for a new approach in MS management?	13.45-14.45 Britannia - Your advice,	13.45-14.45 Avexis - Predict, Prevent, Repair: Gene therapy for motor neurone diseases					09:30-10:00 Co 16:15-16:45 Coff					
SYMP 05		SYMP 06	TC 10	TC 11	TC 12	os	TC 13	CbW 06		TC 14		os	
15:00 - 17:00 EAN / ESO: Update on acute stroke treatment		15:00 - 17:00 EAN / EFAS: Highlights in the expanding arena of auto- nomic disorders	15:00 - 18:15 EAN / MDS-ES: State-of-the-art in dystonia pathophsiology and managment - Level 3		15:00 - 18:15 How to handle safety issues in MS treatment - Level 2	15:00 - 16:15 Epilepsy 2	15:00 - 18:15 Functional neurological disorders: a reappraisal of the nothingness - Level 2	15:00 - 16:30 EAN / EPNS: Case-based management of the paediatric		15:00 - 18:15 Recovery from mild Traumatic Brain Injury and repetitive concussions - Level 3		15:00 - 16:00 Neuro-opht- halmology/ neuro-otology	
os	i					OS		CONT 02	os			OS	os
17:15 - 18:30 Cerebrovascu- lar diseases 3						16:45 - 18:30 Movement disorders 2			16:45 - 18:30			17:00 - 18.15 rology/neuropsy- g and dementia 2	17:00 - 18.15 Neuroimmu-
	EPR 305	EPR 306	EPR 307	EPR 308	EPR 309		EPR 311	EPR 312	EPR 316	EPR 314	EPR 315	EPR 304	EPR 310
	18:30 - 19:20 Headache and pain 5	18:30 - 19:05 Infectious Diseases 2	18:30 - 19:30 Movement disorders 5	18:30 - 19:25 MS and related disorders 7	18:30 - 19:25 MS and related disorders 8		18:30 - 19:10 Muscle and NMJ disease 3	18:30 - 19:15 Neuroge- netics 2	18:45 - 19:50 Sleep disor- ders 3	18:30 - 19:20 Neurorehabi- litation; Spinal cord and root disorders	18:30 - 19:25 Peripheral nerve disorders 2	18:30 - 19:30 Epilepsy 3	18:30 - 19:25 MS and related disorders 9



Tuesday, 26 May

Session Overview

Auditorium	Oslo	Vienna	Lisbon	Amsterdam	Copenhagen	Berlin	Budapest	CbW Room	Seville	Paris	HoC room	Helsinki	Istanbul
SYMP 07	laS 08	SYMP 08	os	os	os	SPS 10			OS		HoC 09		
08:00 - 10:00 Epilepsy - what to do with a pharmacore- sistant patient?	Hot topics in neuro-ophthal- mology	08:00 - 10:00 Non-Alzheimer pathology in the elderly: what to do?	MS and related	08:30 - 10:00 Sleep disor- ders 2					08:30 - 10:00 Neurotrau- matology; neurorehabili- tation		08:00 - 10:00 EAN / ESNCH: Neurosonology advanced - Level 2		
PLEN 04 10:30 - 12:30 Highlights of the congress and Breaking News								10:00-10:30 Cof 14:30-15:00 Cof					

F	C 18	TC 15 TC 16 TC 1	18 CdS
]] ; ;	3.00-16.30 are erebrovascular onditions - evel 2	13.00-16.30 Inherited neuropathies: from genetic diagnosis to management - Level 2 13.00-16.30 Integrative neuropathies: from genetic disorders - Level 3 13.00 Integrative neadache diagnosis to headache neuropathies. Level 3 disorders - Level 3 disorders - Level 2 tevel 3 tions of tions.	e Basic statistics for neurologists ditions -





FW Focused Workshop
PLEN Plenary Symposium
SSS Special Session
SYMP Symposium
OS Oral Session
EPR ePresentations

^{*} Hands-on Courses will be converted into "How do I examine" courses for this virtual congress





Plenary Symposia

Friday, 22 May 18:30 – Main Auditorium Opening fri 22 May

Sunday, 24 May 10:00-12:00 Main Auditorium

Presidential Symposium:

Named Lectures and Brain Prize Lecture

Monday, 25 May 10:00-12:00 Main Auditorium

Overarching theme Symposium

Time for Action. Predict. Prevent. Repair.

Tuesday, 26 May 10:30-12:30 Main Auditorium

Highlights of the congress and breaking news

Covid-19 Special session

Sunday, 24 May 15:00 – 16:30 – Main Auditorium

_ sur 24

Covid-19 infection and possible neurological consequences

- Ethical considerations during the COVID-19 Pandemic
- Diagnosis and medical care of COVID-19
- Neurological manifestations and outcome of SARS-CoV-2 infection
- Virological and neurobiological view on SARS-CoV-2



EAN Congress App

Available for iOS and Android Supported by Roche











Scientific Theatre

Time	Saturday, May 23		5	Sunday, May 24	Monday, May 25			
	organisation/ speaker	lecture title	organisation/ speaker	lecture title	organisation/ speaker	lecture title		
09:30			coffeebreak: Forum talk by 9:30-9:45 MERCK MS treatment decisions and 9:45-10:00 AveXis Gene therapy revolution: ar	•	coffeebreak: Forum talk by industry 9:30-9:45 MERCK Cladribine Tablets RWE: effectiveness beyond the dosing period			
10:00	CoCoCare Prof. Marian Majoie	European guideline education and Cost-Conscious Healthcare – CoCoCare Project	EAN Guideline Production Group Dr. Katina Aleksovska	EAN guideline production	JEB / UEMS Prof. Patrick Cras	UEMS - Section of Neurology (SN)		
10:30	CoCoCare Project Participants	End-of-project workshop, presentation of results and discussion	WBP Women Brain Project Dr. Patricia Pozo-Rosich	Migraine - a key to understand sex differences in the brain	JEB / UEMS Prof. Jan Kuks	EBN - European Board Exam for Neurology		
11:00	EFIC - European Pain Federation Dr. S. Badreh	Introducing the European Pain Forum	RRFS Dr. Luca Cuffaro	The National Representative Network of the RRFS	RRFS Dr. David Garcia Azorin	Headache education project		
11:30	RRFS Dr. Lisa Klingelhoefer	History of the RRFS	EPNS - Eur. Paediatric Neurology Society Prof. Sameer Zuberi	When should the adult neurologist request genetic testing for epilepsy?	EFAS - Eur. Fed. of Autonomic Societies Prof. Walter Struhal	No autonomic lab available – a bed side approach and European Autonomic Training		
12:00			EAPC - Eur. Alliance for Palliative Care Prof. David Oliver	Neurology and Palliative care - how do we develop further collaboration	Italian MS Society Prof. Mario Battaglia	Engaging patients in Multistakeholder Research Initiatives		
12:30			ERN-RND Dr. Sanja Hermanns	Joint webinar series on rare neurological, movement and neuromuscular diseases	ERN-RND Prof. Holm Graessner	Joint webinar series on rare neurological, movement and neuromuscular diseases		
13:00	INUS - Int. Neuro- urology Society Prof. Jalesh Panicker	gy Society and the International Neurourology		rs. Carla Finocchiaro How best to use EU funding: let's start with acronyms and European jargon.				
13:30	ERN-EURO-NMD Prof. Antonio Atalaia	Treatabolome: a rare diseases treatment awareness project	RRFS Dr. Giovanni Di Liberto	Burn-out survey initiative				
14:00	Prof. A. Noyce Wolfson Institute of Preventive Medicine	How should healthcare professionals and health systems respond to the likely demand for genetic testing to assess disease risk?	EBC - European Brain Council Dr. Kristien Aerts	EBRA (European Brain Research Area): Harmonising brain research and funding initiatives in Europe	WBP Dr. Davide Cirillo and Dr. Silvina Catuaro	Sex and gender differences in digital health for brain and mental diseases -an update from the Women's Brain Project		
14:30	RRFS Dr. Vanessa Carvalho	Boost your knowledge with RRFS	EBC - European Brain Council Prof Maura Pugliatti	Rethinking MS in Europe: prioritising integrated services for people with multiple sclerosis	RRFS Dr. Luca Cuffaro	Neurology and Covid-19: residents and research fellows perspective		
15:00	Prof. A. Noyce Wolfson Institute of Preventive Medicine	How should healthcare professionals and health systems respond to the likely demand for genetic testing to assess disease risk?	EFNA Mr. Tadeusz Hawrot	Brain Health as a Global Priority				
15:30	EAN Scientific Committee member	Scientific Panels - what they are and how they work	EFNA Ms. Elisabeth Cunningham	#BrainLifeGoals - an awareness campaign				
	coffeebreak: Forum talk by industry		coffeebreak: Forum talk by	industry	coffeebreak: Forum talk by	industry		
16:15	16:15-16:30 MERCK Switching between high-efficacy treatments:		16:15-16:30 ROCHE Understanding spinal musc how far have we come?	ular atrophy:	16:15-16:30 Medtronic Chronic sensing in DBS: a new paradigm			
	16:30-16:45 GW Pharma Cannabinoid science: under		16:30-16:45 GW Pharma Cannabinoid science: under		16:30-16:45 Natus Normal Values for Electrodiagnostic Studies			
18:30	EPR121	Sleep disorders 1	EPR219	R219 Neuroimmunology 2		Neuro-oncology 2		

Cooperation

EAN is working with several partner societies and organizing its Scientific Programme together with them. Details can be found in the Scientific Programme and in the App. For the virtual congress 2020 special agreements have been made with:

EFAS

European Federation of Autonomic Societies



IFCN-EMEAC

International Federation of Clinical Neurophysiology-Europe-Middle East-Africa Chapter



MDS-ES

Movement Disorders Society- European Section



Their sessions are also marked as such in the Session overview

congress





EAN Industry Network area:

EAN thanks all sponsors for their contributions and making a free-of-charge participation for all neurologists available. Please visit the EAN Industry Network, collect information, meet experts and discuss with our industry partners.

Special thanks go to our Premium sponsors:













Neurohood:

Visit our NPO partners' exhibition area in the EAN Neurohood!

Predict, Prevent, Conquer: Beyond Head Pain

Join us online during the EAN Virtual Congress

ROOM VIENNA

Saturday, 23 May 2020 12:15 - 13:15 (CEST)



LEARNING OBJECTIVES

- Explore new data in CGRP mABs
- Identify elements of productivity and impact to patient
- Recognize the ideal clinical approach based on real world evidence
- Determine ways to bridge clinical trial data to clinical practice

AGENDA

12:15 – 12:25	Chairperson Welcome and Introductions Cristina Tassorelli, MD, PhD (Italy)
12:25 - 12:40	A Current Understanding of the Onset and Efficac of CGRP mAbs Michel Lantéri-Minet, MD, PhD (France)
12:40 - 12:55	CGRP mAbs Efficacy Measured Over Time: Weekly and Monthly Persistence Dagny Holle-Lee, MD, PhD (Germany)
12:55 – 13:10	The Impact of CGRP mAbs on Work, Family, and Social Life Christian Lucas, MD, PhD (France)
13:10 - 13:15	Panel Discussion, Questions and Answers All faculty

PP-LN-FR-0035 April 2020





сy